Cochrane · systematic review · CD011600
Inhaled corticosteroids with combination inhaled long‐acting beta2‐agonists and long‐acting muscarinic antagonists for chronic obstructive pulmonary disease
van Geffen, WH, Tan, DJ, Walters, JAE, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
9
current version
GRADE rated
8
No studies
1
Included studies
NR
No studies 1 · 11.1%Ungraded 0 · 0%Very low 0 · 0%Low 5 · 55.6%Moderate 2 · 22.2%High 1 · 11.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Triple therapy compared to LABA/LAMA combination for COPD
Population: people with stable COPD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes (weighted Triple therapy vs LABA/LAMA combination | no estimate extracted | NR | No studies |
Moderate‐to‐severe exacerbations (rate) Triple therapy vs LABA/LAMA combination | RR 0.74 [0.67, 0.81] | 4 studies · 15397 participants | Low Downgraded: inconsistency, indirectness |
Severe exacerbations (rate) Triple therapy vs LABA/LAMA combination | RR 0.75 [0.67, 0.84] | 3 studies · 14131 participants | Low Downgraded: inconsistency, indirectness |
Respiratory HRQoL measured by SGRQ, ≥ 4‐point decrease from baseline (lower scores indicate better HRQoL) Triple therapy vs LABA/LAMA combination | OR 1.35 [1.26, 1.45] | 3 studies · 14070 participants | High |
Pneumonia (labelled as an SAE) Triple therapy vs LABA/LAMA combination | OR 1.74 [1.39, 2.18] | 4 studies · 15412 participants | Moderate Downgraded: indirectness |
All‐cause SAEs Triple therapy vs LABA/LAMA combination | OR 0.95 [0.87, 1.03] | 4 studies · 15412 participants | Low Downgraded: imprecision, indirectness |
Symptom score TDI, ≥ 1‐unit increase (lower scores indicate worse dyspnoea) Triple therapy vs LABA/LAMA combination | OR 1.33 [1.13, 1.57] | 1 study · 3044 participants | Moderate Downgraded: imprecision |
Lung function, change in trough FEV1 (mL) Triple therapy vs LABA/LAMA combination | MD 38.68 [22.58, 54.77] | 4 studies · 11352 participants | Low Downgraded: inconsistency, indirectness |
Mortality (all‐cause) Triple therapy vs LABA/LAMA combination | OR 0.7 [0.54, 0.9] | 4 studies · 15397 participants | Low Downgraded: imprecision, indirectness |